Birdwatch Note
2023-02-03 15:26:42 UTC - NOT_MISLEADING
"Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19." https://pubmed.ncbi.nlm.nih.gov/33191178/
Written by C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1620989452410839042
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1621530626703638528
- noteId - 1621530626703638528
- participantId - C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3
- noteAuthorParticipantId -
- createdAtMillis - 1675438002645
- tweetId - 1620989452410839042
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 1
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- "Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19." https://pubmed.ncbi.nlm.nih.gov/33191178/
Note Ratings
| rated at | rated by | |
| 2023-02-03 14:40:51 -0600 | 08956573BB2DC88E23E98EE7F3B4E96E8DD83B6A4D0EBCA73CA0D23CA67550C1 | Rating Details |
| 2023-02-03 13:29:40 -0600 | 08D1436C3AAA88072011D6550F1C0653D28AAFD8D0FB3B0E78B749741A56BEA8 | Rating Details |
| 2023-02-03 17:13:37 -0600 | 1D5915B2B9794B1A6850C45970B90FA43C2908887BE1108A605F0B8BADE23260 | Rating Details |
| 2023-02-03 13:02:07 -0600 | 1E63C4F17963B9C5B4489BFDF29FE99946F4AFDBE9F44C5F9A9F6119EB7A78A4 | Rating Details |
| 2023-02-03 14:48:29 -0600 | 27F45B11737E318FE6CA2ACF4A5D5A318F689F7E042F97B8D1972CB378ACCD17 | Rating Details |
| 2023-02-03 10:02:08 -0600 | 3440E327FFC09396E77E3C806B2CE63500A27905ABDA4DA599C2EFB3935307B4 | Rating Details |
| 2023-02-03 14:21:11 -0600 | 38F57417A47C7F38549E285E1BB490DC6AD51F85D7882AD95D08F0E48876279E | Rating Details |
| 2023-02-03 18:01:47 -0600 | 45B8EF43682258D990F1C39DD9C1C131E030B7B116A1A874CAD37AED55F98C04 | Rating Details |
| 2023-02-03 12:52:11 -0600 | 4721277D9A85FE53E4D00FCA752E084F16D707771CC4D883B271774693811677 | Rating Details |
| 2023-02-03 13:36:45 -0600 | 4A08A16EDFA31E6D7BD170AEC8253C9D43F3C0037AEE1AD46D0D9429C506C92C | Rating Details |
| 2023-02-03 13:04:20 -0600 | 4B1429D6885919E358CFCE8B1A0E97C6E11A5F7DF1CDE08B3F1E91F17AA41779 | Rating Details |
| 2023-02-03 14:31:31 -0600 | 4B8E3805479CF2DFF3103A678F7D961EFB09205C8680C65416814F36A17258BE | Rating Details |
| 2023-02-03 12:43:09 -0600 | 51B4A1BFAD2360B41B479F1D3F7781ECF866C2C1116AC6185FC15AD8D5C76D81 | Rating Details |
| 2023-02-03 12:23:52 -0600 | 547B46B38A1CB3060240F9F561852ADB212E08AA27CDAE1D9BE8DDCD9A5D2518 | Rating Details |
| 2023-02-03 09:56:05 -0600 | 5EDC2B8BBEA2C25FBA40E8849AF6DD751A4AE52F674E4E2311C09F82909AD4F8 | Rating Details |
| 2023-02-03 14:25:36 -0600 | 5F9CAB5B77BAC1DFA4A993ED02C530F4D7A865B79C321210EB2855215A04BF55 | Rating Details |
| 2023-02-03 13:39:13 -0600 | 67B71D4D40446972C7423409BD3092D8EA9A020EDE5B273D041ED7A121D96D02 | Rating Details |
| 2023-02-03 21:00:14 -0600 | 67DA9E0C57FAE2F8883695B1451E543958D5B75B03C243665F060BB5CD8E68EF | Rating Details |
| 2023-02-03 13:35:26 -0600 | 7DAF7E766C91C4681BD9E35A65ED1244CD021FD7E551BF6AB85D6DF31D7EAC10 | Rating Details |
| 2023-02-03 15:22:37 -0600 | 7F9F034D4E3EA32F07294353979742DC043CD399298C671937FEAB0CD2CB85F1 | Rating Details |
| 2023-02-03 15:06:12 -0600 | 83FA4F47B08E136BEB7BB309D6D03406B819B3C4D7AA03849FDBD160F91ABCEF | Rating Details |
| 2023-02-03 12:42:48 -0600 | 8427F8572CD869F7475603437B41BF090E25627EF464BDC05F6AA3F1CF09AEE4 | Rating Details |
| 2023-02-03 15:18:04 -0600 | 90919536C4FC3F239E767F02882DA6579953D4D3D91EA1DB7CC56AE127984613 | Rating Details |
| 2023-02-06 08:03:52 -0600 | 9E6A702AFAAC8E2CCAC2A211E9D2195209EECC067BBAF52EF25BC3DE084DE302 | Rating Details |
| 2023-02-03 13:01:30 -0600 | A30E23B01F927C4387616E33DE422C96B4F9A9B45B8ACA619267391F3D77B5A8 | Rating Details |
| 2023-02-03 18:05:27 -0600 | AACCC71FD9DEFAD8C08C21220E7DF9B0D17A651880639CC58F24999A3ECE55A8 | Rating Details |
| 2023-02-03 12:49:14 -0600 | B1263C396E1B79C0711D9004397C9A2CCB1893B2A3ED0F51ABB07298D01E4140 | Rating Details |
| 2023-02-03 15:23:41 -0600 | B47C11739EC126864050D56E12ED40AED7DBFC96FD8A02889615832515A4A680 | Rating Details |
| 2023-02-03 13:38:43 -0600 | D27C30C172A1546D9A97EEA1DA7356DAABD033DE28532862BE3F6D72189EBF93 | Rating Details |
| 2023-02-03 09:32:21 -0600 | DC558C558B18CC2FF47FE5DFE09BEAC740ED65F17FC27F35DECC528D0AA389AD | Rating Details |
| 2023-02-04 06:07:13 -0600 | E02B39324264A848F4272C83E565B2E9FC2A3FD268BFE5D1663197769B8348B8 | Rating Details |
| 2023-02-09 15:19:22 -0600 | E67C36BA363538055B9894BA056E5590B02FC35983EBEBCA188DE70998090D71 | Rating Details |
| 2023-02-03 15:03:36 -0600 | EBB06926CD93BD00887BCD411F91C9FF7072D8B7C9F35DB8AF4FB1CCE18C6049 | Rating Details |
| 2023-02-03 15:33:05 -0600 | EC2E51AE8C64AE6C0C58E504DFB75E133ECF8F5D0FAC60A72EFC1A51DC264969 | Rating Details |
| 2023-02-03 14:18:24 -0600 | F810B9A117A15B206340CC72B29D65263DC4B812622393BFCBE22D0EE5EE3DFF | Rating Details |
| 2023-02-03 12:52:11 -0600 | Rating Details | |
| 2023-02-03 13:02:07 -0600 | Rating Details | |
| 2023-02-03 18:01:47 -0600 | Rating Details | |
| 2023-02-03 15:22:37 -0600 | Rating Details | |
| 2023-02-03 13:38:43 -0600 | Rating Details | |
| 2023-02-03 13:04:20 -0600 | Rating Details | |
| 2023-02-03 21:00:14 -0600 | Rating Details | |
| 2023-02-03 15:03:36 -0600 | Rating Details | |
| 2023-02-03 14:40:51 -0600 | Rating Details | |
| 2023-02-03 15:33:05 -0600 | Rating Details | |
| 2023-02-03 17:13:37 -0600 | Rating Details | |
| 2023-02-03 14:25:36 -0600 | Rating Details | |
| 2023-02-03 15:06:12 -0600 | Rating Details | |
| 2023-02-04 06:07:13 -0600 | Rating Details | |
| 2023-02-03 12:49:14 -0600 | Rating Details | |
| 2023-02-06 08:03:52 -0600 | Rating Details | |
| 2023-02-03 09:32:21 -0600 | Rating Details | |
| 2023-02-03 12:42:48 -0600 | Rating Details | |
| 2023-02-03 13:35:26 -0600 | Rating Details | |
| 2023-02-03 13:39:13 -0600 | Rating Details | |
| 2023-02-03 13:01:30 -0600 | Rating Details | |
| 2023-02-03 13:36:45 -0600 | Rating Details | |
| 2023-02-03 10:02:08 -0600 | Rating Details | |
| 2023-02-03 14:18:24 -0600 | Rating Details | |
| 2023-02-03 12:23:52 -0600 | Rating Details | |
| 2023-02-03 15:23:41 -0600 | Rating Details | |
| 2023-02-03 09:56:05 -0600 | Rating Details | |
| 2023-02-03 13:29:40 -0600 | Rating Details | |
| 2023-02-03 14:21:11 -0600 | Rating Details | |
| 2023-02-03 14:48:29 -0600 | Rating Details | |
| 2023-02-09 15:19:22 -0600 | Rating Details | |
| 2023-02-03 14:31:31 -0600 | Rating Details | |
| 2023-02-03 15:18:04 -0600 | Rating Details | |
| 2023-02-03 18:05:27 -0600 | Rating Details | |
| 2023-02-03 12:43:09 -0600 | Rating Details | |
| 2023-06-09 10:33:34 -0500 | Rating Details |